Predisposing factors for osteoporosis

 

1. During case presentation at your clinic, you are reviewing four women with predisposing factors for osteoporosis. Which patient is least likely to be at risk for osteoporosis?

A. Nehineza, an overweight African American female with family history of uterine cancer
B. Cristina, a Hispanic woman living a sedentary life
C. Park-Gim-Ka, an underweight Asian woman with a history of tobacco use
D. Skylar, a Caucasian woman experiencing early onset of menopause.

2. Densitometry results are given as T-scores, which values would be considered as osteopenia?

3. After prompt analysis of your patient, you decide to institute treatment for osteoporosis. Which class medication is considered as the first-line treatment? Are there any considerations to be taken prior starting therapy? Which recommendations would you provide to the patient regarding this treatment?

 

Sample Solution

The patient least likely to be at risk for osteoporosis is Skylar, a Caucasian woman experiencing early onset of menopause. Osteoporosis is a condition in which bones become weak and brittle due to loss of bone density (Gunn, 2019). Individuals with certain predisposing factors are more likely to develop the condition including being an older female, having low body weight, heavier alcohol consumption and lower levels of physical activity (Cheung & Cheung 2018).

Nehineza has some predisposing factors such as family history uterine cancer though she is overweight which could potentially reduce her risk. Cristina’s sedentary lifestyle increases her chances while Park-Gim-Ka’s underweight status coupled with tobacco use make her more prone. Skylar on other hand does not possess any of these characteristics though she may experience accelerated bone mineral density loss due early onset menopause however this can be offset through healthy nutrition , regular exercise or hormone replacement therapy (HRT)(Kanis et al.,2016) .

In conclusion , Skylar appears be least at risk for developing osteoporosis among four women reviewed during case presentation given that she lacks many common predisposing factors commonly associated with it such as being an older female or having low body weight. Nevertheless it would still beneficial for her receive HRT if deemed necessary along with maintaining a balanced diet plus engaging in regular physical activity all which help reduce the chances of the developing the disease.

Genes that have genetical variation encode enzymes which metobolize drug, drug transporters, or drug targets. Variation in genes that can predict dose and safety of treatment for different types of cancer patient can have harmful influence on these patients’ treatment(25). For instance, polymorphism where in cytochrome P450 enzymes could cause to metabolite to drug slowly or very fast. So patient give an overdose symptoms or no response to drug by changing the pharmacokinetics of drug metabolism, also it may cause an adverse drug reaction(26). Thereby , forecasting optimal dose of drug , inducing the harmful side effects can be provided by using polymorphism(27). In familial breast cancer, patients shows low survival rate to treatment with tamoxifen that is chemotherapeutic drug because of genetic variation in CYP2D6 that is seen as a poor metabolizer (28). There are some studies abour genetic testing on drug label including test for CYP450 polymorphisms.

Prognosis

Insteaf of using clinicopathologic parameters as a biomarker in biochemical testing for prognosis and selection of therapatic way for cancer patient , Genotyping or gene expression profiling by microarray and protein analysis by mass spectrometry is used for prognostic biomarkers with the understanding of the molecular mechanism of cancer subtypes(29).

Biomarkers can be used alone or with combination of other parameters for classify subgroups according to their risk rate and for leading to therapy decision. For example, tissue microarray analysis with combining molecular and clinical biomarker is more efficient than the clasical clinical parameter for patient who has renal cell carcinoma(30).

Approaches and Tools for Personalized Medicine

Instead of using PCR, fluorescence in situ hybridization, immunohistochemistry, and sequencing for personalized medicine testing, high throughput analyses that consist of microarray, mass spectrometry, second generation sequencing, array comparative genomic hybridization, and high-throughput single nucleotide polymorphism (SNP) analysis were started to use after human genome project . These techniques can analyse numerous target at the same time(31). New technologies improve sesitiveness, speciality, trueness of new b

This question has been answered.

Get Answer
WeCreativez WhatsApp Support
Our customer support team is here to answer your questions. Ask us anything!
👋 Hi, Welcome to Compliant Papers.